Project Grant R21AI203703
Award Date 8/3/26
Completion Date 7/31/28
Dollars Obligated $252K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $3.204 million on June 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to study the interaction between TAR RNA and INI1/SMARCB1, a component of the BAF chromatin remodeling complex, and its role in HIV-1 transcriptional regulation and latency reactivation. The research examines how INI1's winged helix DNA-binding domain binds to TAR RNA to facilitate...
- The National Institute of Allergy and Infectious Diseases awarded New York University $841,719 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop low-cost rapid antibody tests for monitoring HIV treatment effectiveness as a complement to conventional PCR viral load testing. The research consolidates quantitative antibody data across 13 assay platforms and 17 longitudinal HIV treatment cohorts spanning 10 countries and all major HIV subtypes. The...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $780,787 on January 27, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on how T cell receptor recognition of peptide ligands shapes memory CD8+ T cell programming. The research will identify features of T cell epitopes, T cell receptor structural modes of recognition, T cell receptor signaling pathways, and genetic and epigenetic regulators...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine a Project Grant totaling $1,486,296 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the human antibody response to Cryptococcus neoformans and survival outcomes in HIV-associated cryptococcal meningoencephalitis, a devastating opportunistic infection of the central nervous system that occurs predominantly in people...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $832,773 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to advance an "induce-and-clear" therapeutic strategy targeting HIV-1 latent cellular reservoirs. The research integrates RNA-based latency reversal with engineered high-avidity antibodies to overcome barriers to immune clearance of persistent HIV infection. The project...
- The National Institute of Allergy and Infectious Diseases awarded Albert Einstein College of Medicine $776,872 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research on serological correlates of survival in HIV-associated cryptococcal meningitis. The research investigates plasma immunoglobulin measures associated with survival and treatment response in people with HIV and cryptococcal meningitis, a devastating CNS infection caused by...
- The National Institute of Allergy and Infectious Diseases awarded San Diego Biomedical Research Institute $992,920 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research on nanoscale imaging of cell surface HIV envelope immune complexes to optimize natural killer cell antibody-dependent cellular cytotoxicity (ADCC) therapeutics. The project integrates nanoscale imaging, machine learning, and in silico protein modeling to characterize the...
- The National Institute of Allergy and Infectious Diseases awarded Icahn School of Medicine at Mount Sinai $100,228 on November 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to map HIV reservoir establishment in human tonsil organoids. The research will characterize nonproductively infected cells—those harboring integrated HIV proviruses that express no viral proteins and thus evade clearance by antiviral treatments and the immune system—as a barrier to HIV...
- The National Institute of Allergy and Infectious Diseases awarded The Trustees of Columbia University in the City of New York $837,291 on August 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop generative AI-driven models that predict human compliance with non-pharmaceutical interventions during infectious disease outbreaks. The project combines behavioral surveys, large-scale mobility data, and large language model agents to address gaps in current...
- The National Institute of Allergy and Infectious Diseases awarded The Salk Institute for Biological Studies $161,868 on June 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to elucidate the mutational pathways and molecular mechanisms through which drug resistance evolves against latest-generation antiretroviral therapy drugs for HIV. The research combines three complementary approaches. First, the work uses Potts sequence-covariation fitness landscape models...